These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36203465)

  • 1. Erratum: Risk factors of brain metastasis and prognosis in HER2-positive breast cancer: A single-institution retrospective analysis from China.
    Front Oncol; 2022; 12():1027199. PubMed ID: 36203465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk Factors of Brain Metastasis and Prognosis in HER2-Positive Breast Cancer: A Single-Institution Retrospective Analysis from China.
    Cai SL; Wang ZH; Chen XG; Han L; Gong GX; Chen YP; Lin XQ; Ma T; Chen HD
    Front Oncol; 2022; 12():905065. PubMed ID: 35832552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum: ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.
    Frontiers Production Office
    Front Oncol; 2019; 9():709. PubMed ID: 31380291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erratum: The Deubiquitinating Enzyme UCHL1 Induces Resistance to Doxorubicin in HER2+ Breast Cancer by Promoting Free Fatty Acid Synthesis.
    Frontiers Production Office
    Front Oncol; 2021; 11():687249. PubMed ID: 33937091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution.
    Pernas S; Petit A; Climent F; Paré L; Perez-Martin J; Ventura L; Bergamino M; Galván P; Falo C; Morilla I; Fernandez-Ortega A; Stradella A; Rey M; Garcia-Tejedor A; Gil-Gil M; Prat A
    Front Oncol; 2019; 9():967. PubMed ID: 31598491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis.
    Hayashi N; Niikura N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Yamauchi H; Saji S; Iwata H
    Breast Cancer Res Treat; 2015 Jan; 149(1):277-84. PubMed ID: 25528021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
    Bringolf L; Pestalozzi B; Fink D; Dedes K
    Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    Yamamura J; Kamigaki S; Fujita J; Osato H; Manabe H; Tanaka Y; Shinzaki W; Hashimoto Y; Komoike Y
    BMC Cancer; 2021 Apr; 21(1):476. PubMed ID: 33926418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up.
    Matsuo S; Watanabe J; Mitsuya K; Hayashi N; Nakasu Y; Hayashi M
    Breast Cancer Res Treat; 2017 Feb; 162(1):169-179. PubMed ID: 28084583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: A retrospective cohort study.
    Lyu X; Luo B
    Cancer Med; 2021 Nov; 10(22):8114-8126. PubMed ID: 34612593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer.
    Han J; Choi YL; Kim H; Choi JY; Lee SK; Lee JE; Choi JS; Park S; Choi JS; Kim YD; Nam SJ; Nam BH; Kwon MJ; Shin YK
    Breast Cancer Res Treat; 2017 Jul; 164(1):41-56. PubMed ID: 28409241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
    Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
    Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erratum: Quantum Dot-Based Immunofluorescent Imaging of Ki67 and Identification of Prognostic Value in HER2-Positive (Non-Luminal) Breast Cancer [Erratum].
    Int J Nanomedicine; 2023; 18():207-208. PubMed ID: 36647440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
    Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
    Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis.
    Chen Q; Ouyang D; Anwar M; Xie N; Wang S; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W; Ouyang Q
    Front Oncol; 2021; 11():661128. PubMed ID: 33747972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk and prognostic factors of breast cancer with liver metastases.
    Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
    BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome.
    Griguolo G; Dieci MV; Giarratano T; Giorgi CA; Orvieto E; Ghiotto C; Berti F; Della Puppa A; Falci C; Mioranza E; Tasca G; Milite N; Miglietta F; Scienza R; Conte P; Guarneri V
    J Neurooncol; 2017 Jan; 131(2):369-376. PubMed ID: 27853958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
    Li X; Zhang X; Liu J; Shen Y
    BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.